Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGILENT TECHNOLOGIES, INC.A · Entity 3062 | Director | August 03, 2020 | August 05, 2020 |
| Icosavax, Inc.ICVX · Entity 94107 | Director | July 28, 2021 | July 28, 2021 |
| LeonaBio, Inc.ATHA · Entity 1487 | Director | May 28, 2021 | June 01, 2021 |
| Passage BIO, Inc.PASG · Entity 7829 | Director | May 27, 2021 | May 28, 2021 |
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Director | May 21, 2021 | May 24, 2021 |
| Prometheus Biosciences, Inc.RXDX · Entity 112175 | Director · and Chairman of the Board | March 16, 2021 | March 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGILENT TECHNOLOGIES, INC.
Report date August 03, 2020 · Filed August 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,374.232 |
Reported balance
After 2020-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-08-03 · Grant · Acquired 212 · Balance 58,374.232 F1: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. F2: 184.863 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors.
F2: 184.863 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan
Icosavax, Inc.
Report date July 28, 2021 · Filed July 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,097 |
Reported balance
Holding disclosure · report date 2021-07-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 124,097 F1: Includes 64,884 shares subject to repurchase by us, which are subject to vesting. |
| Common StockSEC Table I · non-derivative | IndirectBy Leslie D. Yamada 2016 Trust | 627,229 |
Reported balance
Holding disclosure · report date 2021-07-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 627,229 F2: Includes 53,280 shares subject to repurchase by us, which are subject to vesting. F3: The securities reported herein may be deemed beneficially owned by Tadataka Yamada, M.D., who is a co-trustees of the Leslie D. Yamada 2016 Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2031-01-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-07-28 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F4: 25% of the shares subject to the option will vest on 1/14/2022, and 1/48th of the shares subject to the option vest monthly thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2031-04-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-07-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F5: 25% of the shares subject to the option will vest on 3/19/2022, and 1/48th of the shares subject to the option vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 64,884 shares subject to repurchase by us, which are subject to vesting.
F2: Includes 53,280 shares subject to repurchase by us, which are subject to vesting.
F3: The securities reported herein may be deemed beneficially owned by Tadataka Yamada, M.D., who is a co-trustees of the Leslie D. Yamada 2016 Trust.
F4: 25% of the shares subject to the option will vest on 1/14/2022, and 1/48th of the shares subject to the option vest monthly thereafter.
F5: 25% of the shares subject to the option will vest on 3/19/2022, and 1/48th of the shares subject to the option vest monthly thereafter.
LeonaBio, Inc.
Report date May 28, 2021 · Filed June 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.94 · Expires 2031-05-27 | Direct | 13,871 |
Reported balance
After 2021-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-28 · Grant · Acquired 13,871 · Balance 13,871 F1: The shares subject to the option will vest on the earlier of (i) May 28, 2022, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 28, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of (i) May 28, 2022, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 28, 2021.
Passage BIO, Inc.
Report date May 27, 2021 · Filed May 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.83 · Expires 2031-05-26 | Direct | 16,918 |
Reported balance
After 2021-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-27 · Grant · Acquired 16,918 · Balance 16,918 F1: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Phathom Pharmaceuticals, Inc.
Report date May 21, 2021 · Filed May 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.49 · Expires 2031-05-20 | Direct | 12,500 |
Reported balance
After 2021-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-21 · Grant · Acquired 12,500 · Balance 12,500 F1: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.
Prometheus Biosciences, Inc.
Report date March 16, 2021 · Filed March 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,333 |
Reported balance
After 2021-03-16 transaction · row 1
1 source rowRow 1 · 2021-03-16 · Conversion · Acquired 13,333 · Balance 13,333 F1: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-03-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-16 · Conversion · Disposed 133,334 · Balance 0 F1: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2021 Filed Jun 1, 2021 18:13 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 13,871 | $0.00 Strike: $19.94 | $0.00 |
DisclosureSEC source: 0001209191-21-036916 · doc4.xml · derivative · entry 1 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,871 Underlying: Common Stock · 13,871 shares Expires 2031-05-27 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 28, 2022, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 28, 2021. Read SEC document |
| May 27, 2021 Filed May 28, 2021 18:04 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 16,918 | $0.00 Strike: $13.83 | $0.00 |
DisclosureSEC source: 0001209191-21-036629 · doc4.xml · derivative · entry 1 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,918 Underlying: Common Stock · 16,918 shares Expires 2031-05-26 F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 21, 2021 Filed May 24, 2021 17:29 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $35.49 | $0.00 |
DisclosureSEC source: 0001209191-21-035458 · doc4.xml · derivative · entry 1 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-05-20 F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 21:51 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionSeries B Preferred Stock · Derivative | 133,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021221 · doc4.xml · derivative · entry 2 Yamada Tadataka · CIK 0001402530 · Director · and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 21:51 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionCommon Stock | 13,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021221 · doc4.xml · nonDerivative · entry 1 Yamada Tadataka · CIK 0001402530 · Director · and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 22:33 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 212 | $93.91 | $19,908.92 |
DisclosureSEC source: 0001127602-20-022977 · form4.xml · nonDerivative · entry 1 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,374.232 F1 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. F2 · balance_after: 184.863 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan Read SEC document |
| May 21, 2020 Filed May 22, 2020 17:06 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $36.85 | $0.00 |
DisclosureSEC source: 0001209191-20-031809 · doc4.xml · derivative · entry 1 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Tadataka Yamada continuing in service on the Board through such vesting date. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 23:49 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 205 | $73.01 | $14,966.85 |
DisclosureSEC source: 0001127602-20-014252 · form4.xml · nonDerivative · entry 3 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,977.369 F3 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 23:49 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,027 | $73.01 | $74,980.24 |
DisclosureSEC source: 0001127602-20-014252 · form4.xml · nonDerivative · entry 2 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,772.369 F3 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 23:49 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 3,081 | $73.01 | $224,940.73 |
DisclosureSEC source: 0001127602-20-014252 · form4.xml · nonDerivative · entry 1 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,745.369 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock. F2 · balance_after: 355.610 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan Read SEC document |
| March 03, 2020 Filed Mar 3, 2020 18:51 UTC | Passage BIO, Inc. PASG · Entity 7829 | PurchaseCommon Stock | 6,500 | $18.00 | $117,000.00 |
DisclosureSEC source: 0001209191-20-015648 · doc4.xml · nonDerivative · entry 1 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656,149 Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 18:03 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 33,836 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014704 · doc4.xml · derivative · entry 1 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,836 Underlying: Common Stock · 33,836 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vests as to 2.778% of the total shares monthly, commencing March 27, 2020, with 100% of the total shares vested on February 27, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 18:35 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 250.974 | $82.00 | $20,579.87 |
DisclosureSEC source: 0001127602-19-012835 · form4.xml · nonDerivative · entry 3 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,308.759 F4 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 18:35 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,254.87 | $82.00 | $102,899.34 |
DisclosureSEC source: 0001127602-19-012835 · form4.xml · nonDerivative · entry 2 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,057.785 F3 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors that vest quarterly in 25% increments, with the first vesting on the date of grant. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 18:35 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 2,823 | $82.00 | $231,486.00 |
DisclosureSEC source: 0001127602-19-012835 · form4.xml · nonDerivative · entry 1 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,802.915 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock. F2 · balance_after: 332.831 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 22:33 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,438.063 | $67.47 | $97,026.11 |
DisclosureSEC source: 0001127602-18-012676 · form4.xml · nonDerivative · entry 3 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,647.084 F4 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors that vest quarterly in 25% increments, with the first vesting on the date of grant. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 22:33 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 287.613 | $67.47 | $19,405.25 |
DisclosureSEC source: 0001127602-18-012676 · form4.xml · nonDerivative · entry 2 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,209.021 F3 · shares: Shares of the Company's common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 22:33 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 2,876 | $67.47 | $194,043.72 |
DisclosureSEC source: 0001127602-18-012676 · form4.xml · nonDerivative · entry 1 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,921.408 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock. F2 · balance_after: 267.800 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 22:54 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 386.638 | $53.05 | $20,511.15 |
DisclosureSEC source: 0001127602-17-012254 · form4.xml · nonDerivative · entry 3 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,777.608 F4 · shares: Shares of the Company's common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 22:54 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,933.189 | $53.05 | $102,555.68 |
DisclosureSEC source: 0001127602-17-012254 · form4.xml · nonDerivative · entry 2 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,390.97 F3 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors that vest quarterly in 25% increments, with the first vesting on the date of grant. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 22:54 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 3,866 | $53.05 | $205,091.30 |
DisclosureSEC source: 0001127602-17-012254 · form4.xml · nonDerivative · entry 1 Yamada Tadataka · CIK 0001402530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,457.781 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock. F2 · balance_after: 265.402 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.